LLY
Eli Lilly and Company
Stock
$1,184.78+1.32 (+0.11%)Close Sep 28, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $28.1B | $16.8B | $8.8B | $4.2B | $7.6B | $7.4B | $6.5B | $4.8B | $5.5B | $5.6B | $4.9B | $3.0B | $4.5B | $5.7B | $5.3B | $7.2B | $6.9B | $4.3B | $7.3B | $5.2B |
| Capital expenditures | $9.9B | $7.8B | $5.1B | $3.4B | $1.9B | $1.3B | $1.4B | $1.0B | $1.2B | $1.1B | $1.0B | $1.1B | $1.2B | $1.0B | $905M | $672M | $694M | $765M | $947M | $1.1B |
| Free cash flow | $18.2B | $9.0B | $3.8B | $792M | $5.7B | $6.1B | $5.1B | $3.8B | $4.3B | $4.5B | $3.8B | $1.9B | $3.3B | $4.7B | $4.4B | $6.6B | $6.2B | $3.6B | $6.3B | $4.1B |
| Stock-based compensation | $649M | $626M | $646M | $629M | $371M | $343M | $308M | $312M | $280M | $281M | $255M | $218M | $156M | $145M | $142M | $147M | $231M | $369M | −$255M | −$282M |
| Buybacks | $6.2B | $4.1B | $2.5B | $750M | $1.5B | $1.3B | $500M | $4.4B | $4.2B | $300M | $600M | $750M | $800M | $1.7B | $721M | $0 | $0 | — | — | — |
| Dividends paid | $5.8B | $5.4B | $4.7B | $4.1B | $3.5B | $3.1B | $2.7B | $2.4B | $2.3B | $2.2B | $2.2B | $2.1B | $2.1B | $2.1B | $2.2B | $2.2B | $2.2B | $2.2B | $2.1B | $1.9B |
| Dividends per share | — | $6.23 | $5.40 | $4.69 | $4.07 | $3.53 | $3.07 | $2.68 | $2.33 | $2.12 | $2.05 | — | — | — | — | $1.96 | $1.96 | $1.96 | $1.90 | — |
| Free cash flow margin | 22.8% | 13.8% | 8.3% | 2.3% | 20.1% | 21.4% | 20.8% | 17.0% | 20.1% | 22.7% | 18.0% | 9.5% | 16.8% | 20.4% | 19.5% | 27.0% | 26.7% | 16.4% | 31.2% | 21.9% |